within Pharmacolibrary.Drugs.ATC.L;

model L03AA19
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.5333333333333326e-07,
    adminDuration  = 600,
    adminMass      = 13.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 5.77e-05,
    k12             = 0.0257,
    k21             = 0.0257
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AA19</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Eflapegrastim is a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) analog, conjugated to a human IgG4 Fc fragment via a polyethylene glycol linker. It is used for the reduction in the duration of severe neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients; healthy volunteers and patients with breast cancer following subcutaneous administration.</p><h4>References</h4><ol><li><p>Jeon, Y, et al., &amp; Lee, H (2022). A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects. <i>Drugs in R&amp;D</i> 22(1) 71–87. DOI:<a href=&quot;https://doi.org/10.1007/s40268-021-00379-8&quot;>10.1007/s40268-021-00379-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34993933/&quot;>https://pubmed.ncbi.nlm.nih.gov/34993933</a></p></li><li><p>Shin, KH, et al., &amp; Yu, KS (2013). Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 27(2) 149–158. DOI:<a href=&quot;https://doi.org/10.1007/s40259-013-0010-0&quot;>10.1007/s40259-013-0010-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23359067/&quot;>https://pubmed.ncbi.nlm.nih.gov/23359067</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AA19;
